Health Care/Hospital

D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline

SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio'...

2024-04-08 15:00 1387

Allianz Partners teams up with Foodbank Australia to improve international students' well being

The partnership will feed over 3,300 international students across three states BRISBANE, Australia, April 8, 2024 /PRNewswire/ -- Allianz Partners has partnered with Foodbank Australia to help alleviate the burden of financial hardship and food insecurit...

2024-04-08 13:24 8520

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK...

2024-04-08 08:47 1761

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research...

2024-04-08 08:30 1251

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2024-04-08 08:00 2424

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three pre...

2024-04-08 07:58 1482

IMPACT IN ACTION: Cure Brain Cancer Foundation Launches Inaugural 5-Year Guardian Trust Early Career Fellowship valued at $575,000

SYDNEY, April 8, 2024 /PRNewswire/ -- In a historic first, Cure Brain Cancer Foundation proudly unveiled the launch of its groundbreaking 5-Year Guardian Trust Early Career Fellowship, valued at$575,000. The Guardian Trust Early Career Fellowship represents a bold commitment to fostering a new g...

2024-04-08 07:00 1415

Antengene Presents Four Preclinical Posters at AACR 2024

SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...

2024-04-06 08:30 3646

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

PARIS, April 6, 2024 /PRNewswire/ -- At the Gamers Assembly in Poitiers, France , Optic 2000 & AUSTRALIEGAD set the best video game players an ambitious challenge: to take on a blind player, equipped with an innovative device, in one of the most legendary games. It was an inspiring experience, des...

2024-04-06 00:35 3088

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at th...

2024-04-05 19:00 1917

HSA approves new asthma indication for GSK's Trelegy Ellipta, the first once-daily single inhaler triple therapy approved for use in the treatment of both asthma and COPD in Singapore

SINGAPORE, April 5, 2024 /PRNewswire/ -- GSK Singapore announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 yea...

2024-04-05 16:00 3096

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Inve...

2024-04-05 08:00 1836

Datasea Enters into a Sales Agreement for its Acoustic Products Bringing its Evolutionary Technology to Market in a Strategic Milestone to Develop Rapid Online Sales

BEIJING, April 4, 2024  /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and C...

2024-04-04 22:00 2035

Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting

BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microen...

2024-04-04 22:00 1719

LBB Specialties Announces Principal Partnership with VIZOR

NORWALK, Conn., April 4, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution in North America, announces a new partnership with VIZOR®, a global leader in Zinc Oxide Powders and Dispersions. LBB Specialties will be VIZOR's exclusive channel part...

2024-04-04 21:01 2114

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

ROME, April 4, 2024 /PRNewswire/ -- IRBM, a leader in the field of drug discovery, announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting occurring inSan Diego, April 5-10. The...

2024-04-04 21:00 3143

China Medical University Hospital (CMUH) Ranked Global No.1 Smart Hospital in HIMSS Digital Health Indicator 2023

CMUH has been awarded DHI top hospitals twice in a row TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) has achieved a global top score, 370/400, for the Healthcare Information and Management Systems Society (HIMSS) Digital Health Indicator(DHI)in 2023. T...

2024-04-04 20:30 2533

China Medical University Hospital (CMUH) Explores ' BrainHealth ' to Scrutinize Dementia within a Minute

TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- In clinical practice, neurologists scrutinize dementia patients with using numerous tools, including medical history, blood tests, cognitive testing, mental assessment, medical imaging and electro-physiological signal testing. Patients usually spend...

2024-04-04 20:30 2860

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market

ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic medical devices and surgery.   JENA, Germany and DUBLIN, Calif., April 4, 2024 /PRNewswire/ -- Carl...

2024-04-04 19:00 4042

NEXTCHEM (MAIRE) TO COMBINE ITS PROPRIETARY GREEN AMMONIA TECHNOLOGY WITH VALLOUREC'S HYDROGEN STORAGE SYSTEM TO OFFER AN INTEGRATED SOLUTION FOR "POWER-TO-X" PROJECTS

* Upon completion of joint feasibility studies, NextChem Tech will act as the exclusive global licensor of the integrated technology package combining NEXTCHEM's small-scale green ammonia production technology with Vallourec's hydrogen storage system MILAN, April 4, 2024 /PRNewswire/ -- MAIRE a...

2024-04-04 18:44 2917
1 ... 104105106107108109110 ... 848

Week's Top Stories